Developer docs
API playgroundTry for free, no card

Search company profiles

ExThera Medical

Full company profile

uuid0002cip

Namestring
ExThera Medical
Legal namestring
ExThera Medical Corporation
Company typeenum
Private
Founded yearint
2007
Descriptiontext

ExThera Medical Corporation is a privately held, development-stage medical device company founded in 2007 and headquartered in Martinez, California. The company is developing extracorporeal blood filtration devices that use proprietary microbead adsorption media coated with chemically-bonded modified heparin to mimic the heparan sulfate receptors on human cells, enabling pathogens and circulating tumor cells to bind to the beads and be removed from a patient's bloodstream during hemoperfusion.

The company's product portfolio consists of two investigational devices. The Seraph 100 Microbind Affinity Blood Filter is a single-use extracorporeal hemoperfusion device designed to reduce pathogen levels in patients with severe bloodstream infections and sepsis; it was the first and only pathogen adsorption therapy to receive FDA Emergency Use Authorization for COVID-19 treatment in 2020 but has not received FDA market approval. The ONCObind Procedure Hemoperfusion Filter applies the same platform technology to remove circulating tumor cells from blood and received an FDA Investigational Device Exemption in July 2023 for studies in metastatic pancreatic ductal adenocarcinoma, with Phase I of the OSCAR I study completed in September 2024 reporting a 94% average reduction in circulating tumor cells after a single use.

ExThera has no commercial revenue and no commercially approved products in the United States. Its business model is contingent on future regulatory clearance, with planned go-to-market centered on direct sales to hospital ICUs, infectious disease departments, and oncology centers, supported by clinical trial partnerships with major institutions including Mayo Clinic and OU Health Stephenson Cancer Center. Capital formation has come primarily from venture funding led by Fresenius Medical Care Ventures ($15.3M Series B in August 2023), with additional Department of Defense sponsorship of sepsis trials. The company faces material regulatory headwinds, including a 2026 DOJ deferred prosecution agreement and FDA warning letter related to adverse event reporting and unauthorized promotional claims.

Short descriptiontext

ExThera Medical is a development-stage medical device company developing extracorporeal blood filtration devices (Seraph 100 and ONCObind) that use heparin-mimicking microbeads to remove pathogens and circulating tumor cells from bloodstream, targeting hospital ICUs and oncology centers pending FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMartinez, United States
HQ citystring
Martinez
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
extracorporeal blood filtration, pathogen adsorption therapy, hemoperfusion devices, circulating tumor cell removal, blood purification technology
Industry2 codes
PRIMARYHLAHAKAE
Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories)
SECONDARYHLAHAAAH
Blood Bank, Transfusion Medicine & Immunohematology
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Therapeutic Apheresis and Blood Filtration Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

ExThera Medical is a development-stage company with no commercial revenue. Its Seraph 100 and ONCObind devices are investigational products not yet approved by FDA for commercial sale. The company is pursuing regulatory approval in the US and EU markets.

extheramedical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ONCObind
Description

ONCObind Procedure Hemoperfusion Filter for removing circulating tumor cells (CTCs) from blood of patients with metastatic cancer. FDA has granted Investigational Device Exemption (IDE) for study in patients with metastatic pancreatic ductal adenocarcinoma.

extheramedical.com
+1 more record
Core offering1 text field

ExThera Medical develops single-use extracorporeal hemoperfusion devices that use microbead adsorption media coated with chemically-bonded modified heparin to mimic human cell receptors. The Seraph 100 is designed to reduce pathogens (bacteria, viruses, fungi) in the bloodstream of patients with severe infections, while the ONCObind procedure applies the same platform to filter circulating tumor cells (CTCs) from blood in metastatic cancer patients. Both devices are currently investigational in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 94% average reduction in circulating tumor cells after single use of Oncobind procedure
+2 more records
Product overview1 text field

ExThera Medical develops extracorporeal blood filtration devices for medical applications. The company's product portfolio consists of two main investigational devices: the Seraph 100 Microbind Affinity Blood Filter, a single-use extracorporeal device that uses heparin-mimicking microbeads to adsorb pathogens from the bloodstream and was previously authorized for emergency COVID-19 use in the US; and the ONCObind Procedure Hemoperfusion Filter, which applies similar adsorption technology to remove circulating tumor cells from the blood of cancer patients. Both devices are investigational in the United States and have not received FDA market clearance or approval.

Product and service2 records
1Seraph 100 Microbind Affinity Blood Filter
CategoryTherapeutic apheresis / extracorporeal blood filtration device
Description

A single-use extracorporeal hemoperfusion device that uses microbeads coated with molecular heparin receptor sites to adsorb and remove pathogens (bacteria, viruses, fungi) from the bloodstream of patients with severe infections, intended as an adjunctive treatment of bloodstream infections for use in hospitals, clinics, and austere environments. The device mimics heparan sulfate receptors on human cells that pathogens attack when invading the body.

2ONCObind Procedure Hemoperfusion Filter
CategoryTherapeutic apheresis / oncology blood filtration device
Description

Extracorporeal blood filtration procedure designed to target and filter out circulating tumor cells (CTCs) from the bloodstream of cancer patients, based on ExThera's Seraph 100 platform technology. Studied for metastatic cancer treatment applications including pancreatic ductal adenocarcinoma under an FDA Investigational Device Exemption.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research partnership for DARPA's Dialysis-Like Therapeutics program to develop a dialysis-like therapeutic (DLT) intrinsic separation device to treat sepsis in wounded warriors. ExThera's technology was the only device evaluated in the final phase of the competitive program after other technologies were down-selected.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Enrolled first patient for ExThera Medical's PURIFY-RCT II trial to evaluate efficacy of pathogen removal from severely ill patients suffering from pathogen shock. The trial is sponsored by the Department of Defense in collaboration with the Henry M. Jackson Foundation and Uniformed Services University of Health Sciences.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical partner of the University of Oklahoma, enrolled first patient for ExThera Medical's OSCAR I STUDY to evaluate ONCObind procedure for removal of circulating tumor cells in patients with metastatic pancreatic ductal adenocarcinoma.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage medical device company developing extracorporeal blood purification therapies (CytoSorb) for sepsis, cytokine storm, and other critical-care conditions. Direct competitor to ExThera's Seraph 100 in the hospital ICU blood-purification market.

TypeDirect peer
Description

Clinical-stage company developing extracorporeal blood purification therapies for septic shock (PMX cartridge and the PMB hemoperfusion device). Competes with ExThera's pathogen-removal approach for severe bloodstream infections.

TypeEmerging player
Description

Early-stage company developing the Hemopurifier, an extracorporeal blood filtration device targeting viruses and tumor-derived exosomes. Adjacent technology and overlapping use cases in pathogen and cancer-related blood purification.

TypeBroad incumbent
Description

Leading manufacturer of hemoperfusion cartridges widely used in China and expanding globally. Direct overlap with ExThera's hemoperfusion-based pathogen removal technology and target customer base of ICU clinicians.

TypeBroad incumbent
Description

Division of Toray Industries that develops and markets hemoperfusion and other blood purification devices (e.g., Toraymyxin for endotoxin removal). Established global player in extracorporeal sepsis-treatment devices that overlaps with Seraph 100.

6Asahi Kasei Medical
TypeBroad incumbent
Description

Manufacturer of therapeutic apheresis and blood purification products used in critical care settings. Relevant incumbent in the broader extracorporeal blood-treatment category where ExThera operates.

TypeBroad incumbent
Description

Diversified medical products company with established blood therapies, renal care, and continuous renal replacement therapy (CRRT) product lines serving hospital ICUs. Competes broadly with ExThera for ICU blood-treatment budgets and prescriber mindshare.

TypeBroad incumbent
Description

Global leader in dialysis and blood-related technologies, parent of ExThera's lead investor Fresenius Medical Care Ventures. Provides distribution scale and strategic context for evaluating ExThera's commercial pathway.

TypeRegional player
Description

Japanese manufacturer of medical devices including hemodialysis and blood purification systems. Regional incumbent with comparable extracorporeal blood-treatment technology primarily serving Asia-Pacific markets.

TypeEmerging player
Description

Clinical-stage immuno-oncology company with circulating-tumor-cell-related programs. Adjacent in the oncology-circulating-tumor-cell treatment space where ExThera's ONCObind operates, representing an alternative modality for the same clinical problem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ExThera Medical

Therapeutic Apheresis and Blood Filtration Medical Devicesextheramedical.com

ExThera Medical is a development-stage medical device company developing extracorporeal blood filtration devices (Seraph 100 and ONCObind) that use heparin-mimicking microbeads to remove pathogens and circulating tumor cells from bloodstream, targeting hospital ICUs and oncology centers pending FDA approval.

What ExThera Medical does

ExThera Medical Corporation is a privately held, development-stage medical device company founded in 2007 and headquartered in Martinez, California. The company is developing extracorporeal blood filtration devices that use proprietary microbead adsorption media coated with chemically-bonded modified heparin to mimic the heparan sulfate receptors on human cells, enabling pathogens and circulating tumor cells to bind to the beads and be removed from a patient's bloodstream during hemoperfusion.

The company's product portfolio consists of two investigational devices. The Seraph 100 Microbind Affinity Blood Filter is a single-use extracorporeal hemoperfusion device designed to reduce pathogen levels in patients with severe bloodstream infections and sepsis; it was the first and only pathogen adsorption therapy to receive FDA Emergency Use Authorization for COVID-19 treatment in 2020 but has not received FDA market approval. The ONCObind Procedure Hemoperfusion Filter applies the same platform technology to remove circulating tumor cells from blood and received an FDA Investigational Device Exemption in July 2023 for studies in metastatic pancreatic ductal adenocarcinoma, with Phase I of the OSCAR I study completed in September 2024 reporting a 94% average reduction in circulating tumor cells after a single use.

ExThera has no commercial revenue and no commercially approved products in the United States. Its business model is contingent on future regulatory clearance, with planned go-to-market centered on direct sales to hospital ICUs, infectious disease departments, and oncology centers, supported by clinical trial partnerships with major institutions including Mayo Clinic and OU Health Stephenson Cancer Center. Capital formation has come primarily from venture funding led by Fresenius Medical Care Ventures ($15.3M Series B in August 2023), with additional Department of Defense sponsorship of sepsis trials. The company faces material regulatory headwinds, including a 2026 DOJ deferred prosecution agreement and FDA warning letter related to adverse event reporting and unauthorized promotional claims.

ExThera Medical firmographics

Firmographics
Name
ExThera Medical
Legal name
ExThera Medical Corporation
Website
https://extheramedical.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
ExThera Medical is a development-stage medical device company developing extracorporeal blood filtration devices (Seraph 100 and ONCObind) that use heparin-mimicking microbeads to remove pathogens and circulating tumor cells from bloodstream, targeting hospital ICUs and oncology centers pending FDA approval.
Ownership category
akta.pro rank

ExThera Medical industry classification

Industry
Product category
Therapeutic Apheresis and Blood Filtration Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAKAE
Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories)
SECONDARYHLAHAAAH
Blood Bank, Transfusion Medicine & Immunohematology
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Extracorporeal blood filtration
  • Pathogen adsorption therapy
  • Hemoperfusion devices
  • Circulating tumor cell removal
  • Blood purification technology

Where ExThera Medical is headquartered

Location

Headquarters

HQ city
Martinez
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ExThera Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Medical Device Sales: ExThera Medical is a development-stage company with no commercial revenue. Its Seraph 100 and ONCObind devices are investigational products not yet approved by FDA for commercial sale. The company is pursuing regulatory approval in the US and EU markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

ExThera Medical product offering

Product offering

Core offering

ExThera Medical develops single-use extracorporeal hemoperfusion devices that use microbead adsorption media coated with chemically-bonded modified heparin to mimic human cell receptors. The Seraph 100 is designed to reduce pathogens (bacteria, viruses, fungi) in the bloodstream of patients with severe infections, while the ONCObind procedure applies the same platform to filter circulating tumor cells (CTCs) from blood in metastatic cancer patients. Both devices are currently investigational in the United States.

Product overview

ExThera Medical develops extracorporeal blood filtration devices for medical applications. The company's product portfolio consists of two main investigational devices: the Seraph 100 Microbind Affinity Blood Filter, a single-use extracorporeal device that uses heparin-mimicking microbeads to adsorb pathogens from the bloodstream and was previously authorized for emergency COVID-19 use in the US; and the ONCObind Procedure Hemoperfusion Filter, which applies similar adsorption technology to remove circulating tumor cells from the blood of cancer patients. Both devices are investigational in the United States and have not received FDA market clearance or approval.

Differentiator

Problem solved

Functional benefit

Brands

  • ONCObind: ONCObind Procedure Hemoperfusion Filter for removing circulating tumor cells (CTCs) from blood of patients with metastatic cancer. FDA has granted Investigational Device Exemption (IDE) for study in patients with metastatic pancreatic ductal adenocarcinoma.
  • Seraph 100

Products and services

  • Seraph 100 Microbind Affinity Blood Filter A single-use extracorporeal hemoperfusion device that uses microbeads coated with molecular heparin receptor sites to adsorb and remove pathogens (bacteria, viruses, fungi) from the bloodstream of patients with severe infections, intended as an adjunctive treatment of bloodstream infections for use in hospitals, clinics, and austere environments. The device mimics heparan sulfate receptors on human cells that pathogens attack when invading the body.
  • ONCObind Procedure Hemoperfusion Filter Extracorporeal blood filtration procedure designed to target and filter out circulating tumor cells (CTCs) from the bloodstream of cancer patients, based on ExThera's Seraph 100 platform technology. Studied for metastatic cancer treatment applications including pancreatic ductal adenocarcinoma under an FDA Investigational Device Exemption.

Quantifiable outcome

  • 94% average reduction in circulating tumor cells after single use of Oncobind procedure
  • +2 more outcomes

Companies that use ExThera Medical

Customer profile

Segments3 records

Ideal customer profiles3 records

ExThera Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ExThera Medical partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Battelle Memorial InstitutecoreStrategic or Co-development PartnerCollaborative research partnership for DARPA's Dialysis-Like Therapeutics program to develop a dialysis-like therapeutic (DLT) intrinsic separation device to treat sepsis in wounded warriors. ExThera's technology was the only device evaluated in the final phase of the competitive program after other technologies were down-selected.
  • Mayo CliniccoreStrategic or Co-development PartnerEnrolled first patient for ExThera Medical's PURIFY-RCT II trial to evaluate efficacy of pathogen removal from severely ill patients suffering from pathogen shock. The trial is sponsored by the Department of Defense in collaboration with the Henry M. Jackson Foundation and Uniformed Services University of Health Sciences.
  • OU Health Stephenson Cancer CentercoreStrategic or Co-development PartnerClinical partner of the University of Oklahoma, enrolled first patient for ExThera Medical's OSCAR I STUDY to evaluate ONCObind procedure for removal of circulating tumor cells in patients with metastatic pancreatic ductal adenocarcinoma.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

ExThera Medical competitors and assessment

Company assessment

Direct peers

  • CytoSorbents: Commercial-stage medical device company developing extracorporeal blood purification therapies (CytoSorb) for sepsis, cytokine storm, and other critical-care conditions. Direct competitor to ExThera's Seraph 100 in the hospital ICU blood-purification market.
  • Spectral Medical: Clinical-stage company developing extracorporeal blood purification therapies for septic shock (PMX cartridge and the PMB hemoperfusion device). Competes with ExThera's pathogen-removal approach for severe bloodstream infections.

Emerging players

  • Aethlon Medical: Early-stage company developing the Hemopurifier, an extracorporeal blood filtration device targeting viruses and tumor-derived exosomes. Adjacent technology and overlapping use cases in pathogen and cancer-related blood purification.
  • Marker Therapeutics: Clinical-stage immuno-oncology company with circulating-tumor-cell-related programs. Adjacent in the oncology-circulating-tumor-cell treatment space where ExThera's ONCObind operates, representing an alternative modality for the same clinical problem.

Broad incumbents

  • Jafron Biomedical: Leading manufacturer of hemoperfusion cartridges widely used in China and expanding globally. Direct overlap with ExThera's hemoperfusion-based pathogen removal technology and target customer base of ICU clinicians.
  • Toray Medical: Division of Toray Industries that develops and markets hemoperfusion and other blood purification devices (e.g., Toraymyxin for endotoxin removal). Established global player in extracorporeal sepsis-treatment devices that overlaps with Seraph 100.
  • Asahi Kasei Medical: Manufacturer of therapeutic apheresis and blood purification products used in critical care settings. Relevant incumbent in the broader extracorporeal blood-treatment category where ExThera operates.
  • Baxter International: Diversified medical products company with established blood therapies, renal care, and continuous renal replacement therapy (CRRT) product lines serving hospital ICUs. Competes broadly with ExThera for ICU blood-treatment budgets and prescriber mindshare.
  • Fresenius Medical Care: Global leader in dialysis and blood-related technologies, parent of ExThera's lead investor Fresenius Medical Care Ventures. Provides distribution scale and strategic context for evaluating ExThera's commercial pathway.

Regional players

  • Nikkiso: Japanese manufacturer of medical devices including hemodialysis and blood purification systems. Regional incumbent with comparable extracorporeal blood-treatment technology primarily serving Asia-Pacific markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ExThera Medical social profiles

Digital presence

ExThera Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ExThera Medical leadership team

Management profile

Number of profiles

Profiles6 records

ExThera Medical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ExThera Medical funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ExThera Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExThera Medical

What does ExThera Medical do?

ExThera Medical develops single-use extracorporeal hemoperfusion devices that use microbead adsorption media coated with chemically-bonded modified heparin to mimic human cell receptors. The Seraph 100 is designed to reduce pathogens (bacteria, viruses, fungi) in the bloodstream of patients with severe infections, while the ONCObind procedure applies the same platform to filter circulating tumor cells (CTCs) from blood in metastatic cancer patients. Both devices are currently investigational in the United States.

Is ExThera Medical a public or private company?

ExThera Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was ExThera Medical founded?

ExThera Medical was founded in 2007. It employs 11 to 50 people.

Where is ExThera Medical based?

ExThera Medical is headquartered in Martinez, United States, in the North America region.

How does ExThera Medical make money?

One revenue line is on record: medical Device Sales.

Who are ExThera Medical's main competitors?

Direct peers on record are CytoSorbents and Spectral Medical. Emerging players are Aethlon Medical and Marker Therapeutics. Broad incumbents are Jafron Biomedical, Toray Medical, Asahi Kasei Medical, Baxter International and Fresenius Medical Care. Nikkiso is listed as a regional player.

Does ExThera Medical have an API?

No public API is recorded for ExThera Medical.

What industry is ExThera Medical in?

ExThera Medical's product category is Therapeutic Apheresis and Blood Filtration Medical Devices. Its primary akta.pro industry code is HLAHAKAE, Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories), with a secondary code of HLAHAAAH, Blood Bank, Transfusion Medicine & Immunohematology. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AntiguaobserverDr John defends medical practice amidst NYT reportDr. Joseph John defended his medical practice in Antigua against allegations from a New York Times investigation regarding an experimental cancer treatment provided in partnership with US-based ExThera Medical and Quadrant Management. The controversy centers on the use of the Seraph 100 device for blood filtration without FDA approval for cancer, charging patients $45,000 per course despite safety concerns and lack of clinical trial data.CourthousenewsBlood filtration company that claimed cancer cure ducks most of patients' suitU.S. District Judge Maxine M. Chesney dismissed civil RICO, wrongful death, and negligence claims against ExThera Medical Corporation regarding its ONCObind cancer treatment, ruling that plaintiffs failed to prove sufficient causation between the procedure and patient deterioration. However, the judge allowed fraud and product liability claims based on failure to warn about device risks to proceed, while dismissing claims against associated entities due to jurisdictional issues. This legal development follows a separate Department of Justice action where ExThera admitted to defrauding the FDA and agreed to pay a $750,000 penalty.Medical Device and Diagnostic industryFDA Brazenly Calls Out ExThera CMO in Warning LetterThe FDA issued a warning letter to ExThera Medical, specifically calling out Chief Medical Officer Dr. Lakhmir "Mink" Chawla for making unauthorized promotional claims about the company's Seraph 100 device on podcasts, conference presentations, and promotional videos, including statements that the device was "approved in the U.S. for COVID-19" despite lacking FDA approval for any indication. The agency stated the device has no approved PMA (Premarket Approval) and cited Chawla's claims about treating long COVID, cancer, and chronic Lyme disease as evidence of promoting unapproved uses. The article frames FDA's decision to name an individual executive rather than address the company broadly as a deliberate enforcement strategy to hold professionals accountable for unauthorized medical device promotion.Bloomberg Law NewsWhat Medical Device Companies Need to Know About DOJ EnforcementThe Department of Justice is intensifying enforcement against medical device companies, with False Claims Act recoveries totaling $6.8 billion in fiscal year 2025, of which over 83% involved health-care matters, and more than one-third coming from qui tam relators litigating independently. Recent enforcement actions include ExThera Medical's $750,000 deferred prosecution agreement for failing to file adverse event reports related to a blood filtration device, Aesculap's $38.5 million settlement for selling defective knee replacement devices and paying kickbacks to surgeons, and Diopsys's $14.25 million settlement for causing providers to bill Medicare and Medicaid for medically unnecessary vision tests using an uncleared device. The July 2025 renewal of the DOJ-HHS FCA Working Group signals continued heightened scrutiny focused on kickbacks, materially defective devices affecting patient safety, and drug and device pricing.JD SupraNew England Health Care Fraud Strike Force Secures Its First Corporate Resolution in Massachusetts Since Its ExpansionOn March 5, the Department of Justice announced a three-year Deferred Prosecution Agreement with ExThera Medical Corporation after the company's former Chief Regulatory Officer, Sanja Ilic, admitted to concealing the deaths of two cancer patients treated with ExThera's blood filtration devices at clinics in Antigua. Ilic failed to report the adverse events to the FDA to avoid scrutiny that could jeopardize ExThera's $10 million funding and clinical partnerships. Under the DPA, ExThera agreed to pay a $750,000 criminal penalty, establish a $750,000 escrow for civil liabilities, and consent to a $5,694,750 forfeiture order, while Ilic faces up to three years' imprisonment.ReutersBlood filter company, ex-executive face US charges for concealing deathsCalifornia-based ExThera Medical Corp and its former chief regulatory officer, Sanja Ilic, have resolved criminal charges for concealing patient deaths and adverse events related to the company's Seraph 100 blood filtration device used in Antigua. As part of a deferred prosecution agreement, ExThera agreed to pay a $750,000 fine and forfeit $5.69 million, while Ilic pleaded guilty and faces a recommended 34-month prison sentence.Medical NewsEx-Device Exec Covered Up Deaths; CDC Travel Advisory for Polio; F1 Nerve DamageA former executive of ExThera Medical admitted to concealing the deaths of two cancer patients treated with the company's blood filter device from the FDA, according to a Department of Justice announcement. This legal development highlights ongoing regulatory scrutiny over medical device safety and corporate transparency in the healthcare sector.PR NewswireExThera Medical Announces Resolution of Federal InvestigationExThera Medical Corporation has resolved a U.S. Department of Justice investigation into the company's handling of adverse event reporting related to a former employee and a Caribbean distributor. The DOJ fined ExThera $750,000 and placed the company under a deferred prosecution agreement, crediting the company for its cooperation and remediation efforts, including hiring new compliance leadership and implementing enhanced training and auditing procedures. If ExThera fulfills its obligations under the resolution, the charge will be dismissed entirely, allowing the company to resume normal operations.MorningstarExThera Medical Announces Resolution of Federal InvestigationExThera Medical has reached a resolution with the U.S. Department of Justice regarding an investigation into the company's involvement with a Caribbean distributor, with the DOJ fining the company $750,000 for a former employee's failure to adequately investigate and report adverse events to the FDA. The Department of Justice credited ExThera for its cooperation and remediation efforts, including hiring new regulatory compliance leadership and implementing enhanced monitoring procedures, and has agreed to dismiss the charge if the company fulfills its obligations under the resolution. The resolution allows ExThera to move forward following the year-long investigation.